

<b>NCT ID</b>	NCT04111172
<b>Title</b>	A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-10-01
<b>Location</b>	Pennsylvania, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

---

<b>NCT ID</b>	NCT03566355
<b>Title</b>	Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
<b>Phase</b>	Not Applicable
<b>Date Added</b>	2018-06-25
<b>Location</b>	Korea, Republic of
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

---

<b>NCT ID</b>	NCT04185883
<b>Title</b>	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-12-04

<b>Location</b>	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Canada Germany Italy Japan Korea, Republic of Netherlands Spain Taiwan United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03740256
<b>Title</b>	Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-11-14
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	CAdVEC
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT02453620
<b>Title</b>	Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-05-25

<b>Location</b>	California, United States Connecticut, United States Maryland, United States Pennsylvania, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03170960
<b>Title</b>	Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-05-31
<b>Location</b>	Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium France Germany Italy Netherlands Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab, Cabozantinib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03600883
<b>Title</b>	A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100)
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2018-07-26

<b>Location</b>	California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Brazil Canada France Germany Greece Hungary Japan Korea, Republic of Portugal Romania Spain Switzerland
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Anti PD-1/L1, Midazolam, Sotorasib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	PG545 (pixatimod) in combination with nivolumab
<b>Title</b>	PG545 (pixatimod) in combination with nivolumab
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-04-26
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT02668770
<b>Title</b>	Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
<b>Phase</b>	Phase 1
<b>Date Added</b>	2016-01-29
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes

<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, MGN1703
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT02285816
<b>Title</b>	MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2014-11-07
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AdMA3, MG1MA3
<b>Tags</b>	MSS/ MMRp